Overview

Polyhexamethylene Biguanide (PHMB) Ophthalmic Solution in Subjects Affected by Acanthamoeba Keratitis

Status:
Active, not recruiting

Trial end date:
2021-09-30

Target enrollment:

Participant gender:

Summary

Phase 3 study to evaluate the efficacy, safety and tolerability of 0.08% PHMB ophthalmic solution in subjects affected by Acanthamoeba keratitis. A total of 130 subjects will be assigned to one of the following 2 treatment groups: Group 1: 0.08% PHMB + placebo Group 2: 0.02% PHMB + 0.1% propamidine combination therapy

Phase:

Phase 3

Details

Lead Sponsor:

SIFI SpA

Treatments:

Biguanides
Dibrompropamidine
Ophthalmic Solutions
Polihexanide
Polyhexamethylene biguanide
Propamidine